Total
0
Shares
THC Global (ASX:THC) - Group CEO, Ken Charteris
Group CEO, Ken Charteris
Source: THC Global
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • THC Global’s (THC) first Australian-produced medicinal cannabis product is now available for prescription to Australian patients
  • The company’s CBD medicines are 100 per cent Australian made, consisting of cannabis sourced from its Bundaberg cultivation facility, which is then manufactured at its Southport Facility
  • THC Global’s CanndeoCare team will support doctors, pharmacists, and other healthcare professionals regarding the prescription of these medicines
  • The company is now on track to expand its medicines throughout 2020
  • THC Global is currently up 10.6 per cent and shares are trading for 36.5 cents each

THC Global’s (THC) first Australian-produced medicinal cannabis product is now available for prescription to Australian patients.

Launched yesterday, this product is a full-spectrum cannabidiol (CBD) medicine.

Full-spectrum CBD medicines are highly sought after by both clinicians and patients, as they include minor cannabinoids, terpenes and flavonoids and may provide different therapeutic outcomes when compared to CBD medicines formed from combined mixtures.

THC Global’s CBD medicines are 100 per cent Australian made, consisting of cannabis sourced from its Bundaberg cultivation facility, which is then manufactured at its Southport Facility.

CanndeoCare, THC Global’s medical and clinical team, will support doctors, pharmacists, and other healthcare professionals regarding the prescription of these medicines.

The team will provide expert advice and guidance in the technical and medical aspects of medicinal cannabis patient management.

THC says Canndeo, the brand under which the medicines fall, brings together Australian production, affordability, and pharmaceutical quality.

“Getting our wholly Australian medicinal cannabis product to be available for prescribing by Australian doctors is a real milestone for THC Global,” CEO Ken Charteris commented.

“We look forward to increasing the number of Australian patients able to access medicinal cannabis medicines by providing an affordable medicine and supporting both patients and prescribers in the legal and safe use of these products,” he said.

The company is now on track to expand its medicines throughout 2020.

THC Global is up 10.6 per cent on the market and shares are trading for 36.5 cents each at 11:05 am AEST.

THC by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.